195 related articles for article (PubMed ID: 28512788)
21. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.
Özbalak M; Salihoğlu A; Soysal T; Karadoğan İ; Paydaş S; Özdemir E; Yıldız B; Karadurmuş N; Kaynar L; Yagci M; Özkocaman V; Topçuoğlu P; Özcan M; Birtaş E; Göker H; Ferhanoglu B
Ann Hematol; 2020 Feb; 99(2):301-307. PubMed ID: 31844933
[TBL] [Abstract][Full Text] [Related]
22. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM).
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):15-7. PubMed ID: 24870877
[No Abstract] [Full Text] [Related]
23. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
[TBL] [Abstract][Full Text] [Related]
24. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
25. Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.
Kedmi M; Khaustov P; Ribakovsy E; Benjamini O; Avigdor A
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e929-e937. PubMed ID: 34366266
[TBL] [Abstract][Full Text] [Related]
26. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
[TBL] [Abstract][Full Text] [Related]
27. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Eyre TA; Phillips EH; Linton KM; Arumainathan A; Kassam S; Gibb A; Allibone S; Radford J; Peggs K; Burton C; Stewart G; LeDieu R; Booth C; Osborne WL; Miall F; Eyre DW; Ardeshna KM; Collins GP
Br J Haematol; 2017 Nov; 179(3):471-479. PubMed ID: 28857136
[TBL] [Abstract][Full Text] [Related]
28. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
[TBL] [Abstract][Full Text] [Related]
30. Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States.
Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
Clin Ther; 2017 Feb; 39(2):303-310. PubMed ID: 28065438
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
[TBL] [Abstract][Full Text] [Related]
32. Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma.
Kallam A; Armitage JO
Expert Rev Hematol; 2018 Apr; 11(4):293-300. PubMed ID: 29521140
[TBL] [Abstract][Full Text] [Related]
33. FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):7. PubMed ID: 24870873
[No Abstract] [Full Text] [Related]
34. [Treatment and prognosis of relapsed or refractory Hodgkin lymphoma patients ineligible for stem cell transplantation].
Móciková H; Sýkorová A; Stěpánková P; Marková J; Michalka J; Král Z; Burešová L; Belada D
Klin Onkol; 2014; 27(6):424-8. PubMed ID: 25493581
[TBL] [Abstract][Full Text] [Related]
35. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
[TBL] [Abstract][Full Text] [Related]
36. Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era.
Hegerova L; Cao Q; Lazaryan A; McClune BL; Weisdorf DJ; Brunstein CG; Bachanova V
Bone Marrow Transplant; 2017 May; 52(5):697-703. PubMed ID: 28134921
[TBL] [Abstract][Full Text] [Related]
37. T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.
Mariotti J; Devillier R; Bramanti S; Sarina B; Furst S; Granata A; Faucher C; Harbi S; Morabito L; Chabannon C; Carlo-Stella C; Bouabdallah R; Santoro A; Blaise D; Castagna L
Biol Blood Marrow Transplant; 2018 Mar; 24(3):627-632. PubMed ID: 29197681
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for the treatment of Hodgkin lymphoma.
Donato EM; Fernández-Zarzoso M; De La Rubia J
Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170
[TBL] [Abstract][Full Text] [Related]
39. Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents.
Shah H; Jang H; Singh P; Kosti J; Kin A; Alavi A; Ratanatharathorn V; Ayash L; Uberti J; Ramchandren R; Kim S; Deol A
Leuk Lymphoma; 2022 Apr; 63(4):813-820. PubMed ID: 34781825
[TBL] [Abstract][Full Text] [Related]
40. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma.
Mocikova H; Pytlik R; Markova J; Steinerova K; Kral Z; Belada D; Trnkova M; Trneny M; Koza V; Mayer J; Zak P; Kozak T
Leuk Lymphoma; 2011 Sep; 52(9):1668-74. PubMed ID: 21699377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]